JP2003511477A5 - - Google Patents

Download PDF

Info

Publication number
JP2003511477A5
JP2003511477A5 JP2001531090A JP2001531090A JP2003511477A5 JP 2003511477 A5 JP2003511477 A5 JP 2003511477A5 JP 2001531090 A JP2001531090 A JP 2001531090A JP 2001531090 A JP2001531090 A JP 2001531090A JP 2003511477 A5 JP2003511477 A5 JP 2003511477A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001531090A
Other languages
Japanese (ja)
Other versions
JP4062664B2 (ja
JP2003511477A (ja
Filing date
Publication date
Priority claimed from US09/418,594 external-priority patent/US6214874B1/en
Application filed filed Critical
Publication of JP2003511477A publication Critical patent/JP2003511477A/ja
Publication of JP2003511477A5 publication Critical patent/JP2003511477A5/ja
Application granted granted Critical
Publication of JP4062664B2 publication Critical patent/JP4062664B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2001531090A 1999-10-15 2000-10-16 腫瘍の処置における使用のためのノルジヒドログアイアレチン酸誘導体 Expired - Lifetime JP4062664B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/418,594 1999-10-15
US09/418,594 US6214874B1 (en) 1999-10-15 1999-10-15 Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
PCT/US2000/028612 WO2001028494A2 (en) 1999-10-15 2000-10-16 Nordihydroguaiaretic derivatives for use in treatment of tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007263845A Division JP2008019278A (ja) 1999-10-15 2007-10-09 腫瘍の処置における使用のためのノルジヒドログアイアレチン酸誘導体

Publications (3)

Publication Number Publication Date
JP2003511477A JP2003511477A (ja) 2003-03-25
JP2003511477A5 true JP2003511477A5 (enExample) 2005-12-22
JP4062664B2 JP4062664B2 (ja) 2008-03-19

Family

ID=23658774

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001531090A Expired - Lifetime JP4062664B2 (ja) 1999-10-15 2000-10-16 腫瘍の処置における使用のためのノルジヒドログアイアレチン酸誘導体
JP2007263845A Pending JP2008019278A (ja) 1999-10-15 2007-10-09 腫瘍の処置における使用のためのノルジヒドログアイアレチン酸誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007263845A Pending JP2008019278A (ja) 1999-10-15 2007-10-09 腫瘍の処置における使用のためのノルジヒドログアイアレチン酸誘導体

Country Status (10)

Country Link
US (4) US6214874B1 (enExample)
EP (1) EP1231914B1 (enExample)
JP (2) JP4062664B2 (enExample)
CN (1) CN1309381C (enExample)
AT (1) ATE350030T1 (enExample)
AU (1) AU783015C (enExample)
CA (1) CA2387873C (enExample)
DE (1) DE60032795T2 (enExample)
SG (1) SG144712A1 (enExample)
WO (1) WO2001028494A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
US6608108B2 (en) 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
WO2004112695A2 (en) * 2003-05-20 2004-12-29 Erimos Pharmaceutical Llc Methods and compositions for delivery of catecholic butanes for treatment of obesity
US7728036B2 (en) * 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
US20060141029A1 (en) * 2003-05-20 2006-06-29 Erimos Pharmaceuticals Llc Methods and compositions for delivery of catecholic butanes for treatment of diseases
CN100440843C (zh) * 2004-05-12 2008-12-03 华为技术有限公司 一种环网及其业务实现方法
PL1748767T3 (pl) 2004-05-28 2012-08-31 Unigen Inc 1-(3-metylo-2,4-dimetoksyfenylo)-3-(2',4'-dihydroksyfenylo)-propan jako silny inhibitor tyrozynazy
US8440648B2 (en) * 2004-07-20 2013-05-14 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
WO2006014669A2 (en) * 2004-07-20 2006-02-09 Erimos Pharmaceuticals Llc Methods and compositions for treatment of intraepithelial neoplasia
MX2007004025A (es) * 2004-10-06 2007-06-11 Univ Johns Hopkins Uso de derivados del acido nordihidroguaiaretico en el tratamiento de cancer e infecciones microbial y viral resistente a farmacos._.
AU2006208109A1 (en) * 2005-01-27 2006-08-03 Erimos Pharmaceuticals Llc Formulations for injection of catecholic butanes, including NDGA compounds, into animals
JP2009528294A (ja) * 2006-02-23 2009-08-06 エリモス・ファーマスーティカルズ・エルエルシー インフルエンザウイルス感染症の治療方法
US9067875B2 (en) 2006-10-02 2015-06-30 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
EP2076252B1 (en) * 2006-10-02 2014-04-02 Erimos Pharmaceuticals LLC Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
US9005889B2 (en) * 2007-01-16 2015-04-14 The Johns Hopkins University Synergistic antiviral compositions comprising a viral attachment inhibitor, integration inhibitor, and proviral transcription inhibitor
EP2150218B1 (en) * 2007-05-11 2016-07-27 ConvaTec Technologies Inc. Ostomy appliance
ES2998662T3 (en) 2008-07-21 2025-02-21 Unigen Inc Skin-whitening (lightening) compounds
KR20100011963A (ko) * 2008-07-25 2010-02-03 국립암센터 Ndga를 포함하는 트란스글루타미나제 억제용 조성물
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
CA2742986C (en) * 2008-11-07 2015-03-31 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
KR102257469B1 (ko) 2011-03-24 2021-05-27 유니젠, 인크. 디아릴프로판의 제조를 위한 화합물 및 방법
US9084779B2 (en) 2011-05-31 2015-07-21 The Johns Hopkins University Conjugates of nitroimidazoles and their use as chemotherapeutic agents
CN104603094A (zh) * 2012-07-18 2015-05-06 约翰霍普金斯大学 通过四-o-甲基去甲二氢愈创木酸抑制bnip3以及预防和治疗缺血再灌注损伤的方法
CA2941010A1 (en) 2013-02-26 2014-09-04 Triact Therapeutics, Inc. Cancer therapy
EP3044593A4 (en) * 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Cancer therapy
MX391317B (es) 2017-02-17 2025-03-21 Promotora Tecnica Ind S A De C V Composicion mejorada a base de acido norhidroguayaretico.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
US5276060A (en) 1979-06-19 1994-01-04 Block/Chemex, G.P. Methods of treating tumors with compositions of catecholic butanes
DE3009542A1 (de) * 1980-03-13 1981-09-24 Henkel KGaA, 4000 Düsseldorf Desodorierende kosmetische zusammensetzungen
US4774229A (en) 1982-04-05 1988-09-27 Chemex Pharmaceuticals, Inc. Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor
US4880637A (en) * 1985-02-11 1989-11-14 Chemex Pharmaceuticals, Inc. Compositions of catecholic butanes with zinc
US5559149A (en) * 1990-01-29 1996-09-24 Johnson & Johnson Consumer Products, Inc. Skin care compositions containing retinoids
US5646186A (en) * 1994-05-17 1997-07-08 Johnson & Johnson Consumer Products, Inc. Retinoid composition
US6071949A (en) 1995-03-14 2000-06-06 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US5837252A (en) 1996-07-01 1998-11-17 Larreacorp, Ltd. Nontoxic extract of Larrea tridentata and method of making same
US5827898A (en) * 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N

Similar Documents

Publication Publication Date Title
BE2016C059I2 (enExample)
BE2013C060I2 (enExample)
BE2010C009I2 (enExample)
BE2009C057I2 (enExample)
BE2010C018I2 (enExample)
AR028236A3 (enExample)
AU2000236813A8 (enExample)
JP2001060846A5 (enExample)
BR0112866A2 (enExample)
CN300955183S (zh) 连接件
CN3137995S (enExample)
CN3141006S (enExample)
AU2000271150A8 (enExample)
BY6855C1 (enExample)
CL45687B (enExample)
AU2000264849A8 (enExample)
CN3134543S (enExample)
CN3134893S (enExample)
CN3135470S (enExample)
CN3135789S (enExample)
CN3136721S (enExample)
CN3136792S (enExample)
CN3137238S (enExample)
CN3145855S (enExample)
CN3138718S (enExample)